What's Happening?
The U.S. Food and Drug Administration (FDA) has issued a proposed rule that, if finalized, would reverse its previous exclusion of N-acetyl-L-cysteine (NAC) from the definition of 'dietary supplement.' This action would permit NAC-containing products
to be lawfully marketed as dietary supplements, provided they comply with other provisions of the Federal Food, Drug, and Cosmetic Act (FD&C Act). In March 2022, the FDA had stated that NAC-containing products could not be classified as dietary supplements. The proposed rule aims to establish a new regulation titled 'Dietary Ingredients Not Excluded from the Dietary Supplement Definition,' making NAC the first ingredient listed under this new framework. The FDA conducted a comprehensive review and found no safety concerns regarding NAC's use in dietary supplements. NAC products have been sold in the U.S. for over 30 years, and consumer demand for them remains high.
Why It's Important?
This proposed rule is significant for both consumers and the dietary supplement industry. For consumers, it ensures continued access to NAC products, which have been widely available and used for decades. The FDA's acknowledgment of no identified safety concerns after a thorough review provides reassurance regarding the ingredient's safety profile. For the dietary supplement industry, this represents a major regulatory clarification and a potential boost for manufacturers and retailers of NAC-containing products. The FDA's decision to use its rulemaking authority to address this issue sets a precedent for how other ingredients that might face similar definitional challenges could be handled in the future. This move is also categorized as a deregulatory action under President Trump’s Executive Order 14192, aiming to unleash prosperity through deregulation by reducing regulatory burdens on businesses.
What's Next?
The proposed rule is now open for public comment for a period of 60 days. Interested parties, including consumers, industry stakeholders, and healthcare professionals, can submit their feedback, which the FDA will consider before finalizing the rule. During this rulemaking process, the FDA intends to continue its policy of temporary enforcement discretion regarding the sale and distribution of certain NAC-containing products labeled as dietary supplements. This means that while the rule is being finalized, these products can still be marketed, provided they meet other FD&C Act requirements. If the rule is finalized, it will officially establish NAC's status as a lawful dietary ingredient, providing long-term clarity and stability for the market.
Beyond the Headlines
This FDA action highlights the complex regulatory landscape surrounding dietary supplements, particularly concerning ingredients that may also have pharmaceutical applications or a history of use as drugs. The initial exclusion of NAC stemmed from its prior approval as a drug, which under certain interpretations of the FD&C Act, could preclude its classification as a dietary supplement. The FDA's reversal, driven by a lack of safety concerns and long-standing consumer access, demonstrates a pragmatic approach to regulation that balances public health protection with market realities and consumer demand. This case could influence future regulatory decisions for other ingredients that fall into similar gray areas, potentially leading to more flexible interpretations of dietary supplement definitions and fostering innovation within the industry while maintaining safety standards.













